和鉑醫藥-B(02142.HK)授權Moderna使用HCAb發現平臺開發核酸產品
和鉑醫藥-B(02142.HK)公佈,其全資子公司諾納生物與ModernaTX訂立授權及合作協議,戰略合作將專注於使用公司專有的僅重鏈抗體(HCAb)發現平臺發現及開發基於核酸的免疫療法。
Moderna將獲授獨家可再授權許可,以利用公司HCAb平臺衍生的一組針對多個靶點的序列開發核酸產品。Moderna將對協議項下所有即將開展的開發、生產、監管及商業化活動承擔全部責任。
根據協議,諾納生物應收取600萬美元的一次性、不可退還的預付款及根據若幹監管、開發及銷售裏程碑的實現情況收取潛在裏程碑付款最多約5億美元,其將有資格向Moderna收取協議項下所開發的每種產品的分級特許使用權費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.